Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jay Chatfield
Observed names:
Chatfield, Jay,
Jay B Chatfield
Institution:
Cogent Biosciences (United States)
Observed institutions:
Cogent Biosciences (United States),
Kiniksa Pharmaceuticals (United States)
OpenAlex ID:
A5050787670
POSTER: MPN-1161: The Effect of Bezuclastinib on the Pathobiology of Advanced Systemic Mastocytosis: Results From the Pivotal APEX Trial
2026
·
Jay Chatfield
, Tracy I George
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MPN-1154: The Effect of Bezuclastinib on the Pathobiology of Mastocytosis: Changes in Bone Marrow Mast Cells, Tryptase, and KIT p.D816V Variant Allele Frequency From the Pivotal Summit Trial
2026
·
Jay Chatfield
, Tracy I George
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MPN-1161: The Effect of Bezuclastinib on the Pathobiology of Advanced Systemic Mastocytosis: Results From the Pivotal APEX Trial
2026
·
Jay Chatfield
, Tracy I George
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: MPN-1154: The Effect of Bezuclastinib on the Pathobiology of Mastocytosis: Changes in Bone Marrow Mast Cells, Tryptase, and KIT p.D816V Variant Allele Frequency From the Pivotal Summit Trial
2026
·
Jay Chatfield
, Tracy I George
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MPN-1139: Bezuclastinib Expanded Access Program for Patients With Systemic Mastocytosis
2026
·
Lindsay Rein
, Ali Malinowski
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
The Effect of Bezuclastinib on the Pathobiology of Advanced Systemic Mastocytosis: Results From the Pivotal APEX Trial
2026
·
Chatfield, Jay
, George, Tracy I.
, et al.
·
RWTH Publications (RWTH Aachen)
POSTER: MPN-574 Bezuclastinib Expanded Access Program for Patients with Systemic Mastocytosis
2025
·
Lindsay Rein
, Alexandra Malinowski
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MPN-574: Bezuclastinib Expanded Access Program for Patients with Systemic Mastocytosis
2025
·
Lindsay Rein
, Alexandra Malinowski
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Abstract 47: Tapering And Discontinuation Of Background Therapies During The Transition To Rilonacept Monotherapy In Rhapsody, A Phase 3 Clinical Trial Of Rilonacept In Patients With Recurrent Pericarditis
2022
·
Antonio Brucato
, Alistair Wheeler
, et al.
·
Circulation Cardiovascular Quality and Outcomes
Real-world Experience and Unmet Needs in the Current Management of Recurrent Pericarditis: a Physician Survey and Medical Chart Review
2022
·
Ajit B. Raisinghani
, Leo F. Buckley
, et al.
·
Journal of the American College of Cardiology
Show more works
View as search
Works count:
10
Citation count:
H-index:
I10-index:
Year
Topic
Type